Related Experiment Video

Updated: May 9, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Therapeutic decisions in multiple sclerosis: moving beyond efficacy

Wolfgang Brück, Raff Gold, Brett T Lund

    JAMA Neurology
    |August 8, 2013
    PubMed

    Insights

    Newer disease-modifying treatments (DMTs) for multiple sclerosis (MS) target specific pathways but have safety concerns. Understanding their pharmacology is crucial for optimizing patient care and future therapy development.

    Area of Science:

    • Pharmacology
    • Neurology
    • Immunology

    Background:

    • Several new disease-modifying treatments (DMTs) for relapsing-remitting multiple sclerosis (MS) are available or in development.
    • Unlike earlier therapies, newer DMTs have defined molecular targets affecting cell trafficking, survival, function, or proliferation.
    • These newer therapies may present safety issues linked to their structure or metabolism.

    Purpose of the Study:

    • To examine the safety profiles of DMTs for MS.
    • To correlate DMT safety with their pharmacological characteristics, including molecular targets, mechanism of action, structure, and metabolism.
    • To inform clinical decision-making and patient care regarding MS treatment.

    Main Methods:

    • Review of pharmacological characteristics of DMTs for MS.
    • Analysis of molecular targets and mechanisms of action.
    • Evaluation of chemical structure and metabolic pathways.
    • Focus on safety profiles in relation to pharmacological properties.

    Main Results:

    • Newer DMTs target specific cellular processes (trafficking, survival, function, proliferation).
    • Safety concerns associated with newer DMTs may stem from their unique structures and metabolic pathways.
    • Understanding the mechanism of action is key to evaluating safety.

    Conclusions:

    • A thorough understanding of DMT pharmacology is essential for managing MS.
    • Knowledge of DMT mechanisms and metabolism can help mitigate risks and improve benefit-risk profiles.
    • Classifying DMTs by their mechanisms is valuable for sequential or combination therapy considerations.

    More Related Videos

    Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis06:19

    Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

    Published on: September 9, 2022

    Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis05:44

    Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis

    Published on: October 13, 2023

    Related Concept Videos

    Multiple Sclerosis l: Introduction01:19

    Multiple Sclerosis l: Introduction

    Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
    Bioequivalence of Drugs: Drugs with Multiple Indications01:09

    Bioequivalence of Drugs: Drugs with Multiple Indications

    The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
    Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

    Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

    PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
    Therapeutic Drug Monitoring: Affecting Factors01:29

    Therapeutic Drug Monitoring: Affecting Factors

    Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
    Therapeutic Drug Monitoring: Overview and Classification01:16

    Therapeutic Drug Monitoring: Overview and Classification

    Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
    Myasthenia Gravis: Overview and Treatment01:20

    Myasthenia Gravis: Overview and Treatment

    Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
    These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...